These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

395 related items for PubMed ID: 32810506

  • 21. Early Appearance of Principal Symptoms of Kawasaki Disease is a Risk Factor for Intravenous Immunoglobulin Resistance.
    Tajima M, Shiozawa Y, Kagawa J.
    Pediatr Cardiol; 2015 Aug; 36(6):1159-65. PubMed ID: 25753685
    [Abstract] [Full Text] [Related]

  • 22. Giant aneurysms: A gender-specific complication of Kawasaki disease?
    Dietz SM, Kuipers IM, Tacke CEA, Koole JCD, Hutten BA, Kuijpers TW.
    J Cardiol; 2017 Oct; 70(4):359-365. PubMed ID: 28325522
    [Abstract] [Full Text] [Related]

  • 23. Variation in Pharmacologic Management of Patients with Kawasaki Disease with Coronary Artery Aneurysms.
    Selamet Tierney ES, Runeckles K, Tremoulet AH, Dahdah N, Portman MA, Mackie AS, Harahsheh AS, Lang SM, Choueiter NF, Li JS, Manlhiot C, Low T, Mathew M, Friedman KG, Raghuveer G, Norozi K, Szmuszkovicz JR, McCrindle BW, International Kawasaki Disease Registry.
    J Pediatr; 2022 Jan; 240():164-170.e1. PubMed ID: 34474088
    [Abstract] [Full Text] [Related]

  • 24. The time option of IVIG treatment is associated with therapeutic responsiveness and coronary artery abnormalities but not with clinical classification in the acute episode of Kawasaki disease.
    Samadli S, Liu FF, Mammadov G, Wang JJ, Liu HH, Wu YF, Luo HH, Wu Y, Chen WX, Zhang DD, Wei W, Hu P.
    Pediatr Rheumatol Online J; 2019 Jul 31; 17(1):53. PubMed ID: 31366406
    [Abstract] [Full Text] [Related]

  • 25. Heart Rate, Responsiveness to Intravenous Immunoglobulin, and Coronary Artery Aneurysms in Kawasaki Disease.
    Miyakoshi C, Yamamoto Y, Yamakawa M, Fukuhara S.
    J Pediatr; 2018 Sep 31; 200():160-165.e5. PubMed ID: 29793867
    [Abstract] [Full Text] [Related]

  • 26. Evaluation of laboratory predictors for intravenous immunoglobulin resistance and coronary artery aneurysm in Kawasaki Disease before and after therapy.
    Liu J, Ye B, Su D, Qin S, Zhao W, Pang Y.
    Clin Rheumatol; 2023 Jan 31; 42(1):167-177. PubMed ID: 36129563
    [Abstract] [Full Text] [Related]

  • 27. Increased Pentraxin 3 Levels Correlate With IVIG Responsiveness and Coronary Artery Aneurysm Formation in Kawasaki Disease.
    Kitoh T, Ohara T, Muto T, Okumura A, Baba R, Koizumi Y, Yamagishi Y, Mikamo H, Daigo K, Hamakubo T.
    Front Immunol; 2021 Jan 31; 12():624802. PubMed ID: 33912155
    [Abstract] [Full Text] [Related]

  • 28. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).
    Tremoulet AH, Jain S, Kim S, Newburger J, Arditi M, Franco A, Best B, Burns JC.
    Contemp Clin Trials; 2016 May 31; 48():70-5. PubMed ID: 27080929
    [Abstract] [Full Text] [Related]

  • 29. Relationship between post-IVIG IgG levels and clinical outcomes in Kawasaki disease patients: new insight into the mechanism of action of IVIG.
    Goto R, Inuzuka R, Shindo T, Namai Y, Oda Y, Harita Y, Oka A.
    Clin Rheumatol; 2020 Dec 31; 39(12):3747-3755. PubMed ID: 32458247
    [Abstract] [Full Text] [Related]

  • 30. Medium-Term Complications Associated With Coronary Artery Aneurysms After Kawasaki Disease: A Study From the International Kawasaki Disease Registry.
    McCrindle BW, Manlhiot C, Newburger JW, Harahsheh AS, Giglia TM, Dallaire F, Friedman K, Low T, Runeckles K, Mathew M, Mackie AS, Choueiter NF, Jone PN, Kutty S, Yetman AT, Raghuveer G, Pahl E, Norozi K, McHugh KE, Li JS, De Ferranti SD, Dahdah N, International Kawasaki Disease Registry *.
    J Am Heart Assoc; 2020 Aug 04; 9(15):e016440. PubMed ID: 32750313
    [Abstract] [Full Text] [Related]

  • 31. The Clinical Utility and Safety of a New Strategy for the Treatment of Refractory Kawasaki Disease.
    Ebato T, Ogata S, Ogihara Y, Fujimoto M, Kitagawa A, Takanashi M, Ishii M.
    J Pediatr; 2017 Dec 04; 191():140-144. PubMed ID: 29173297
    [Abstract] [Full Text] [Related]

  • 32. Risk factors for coronary artery abnormalities in children with Kawasaki disease: a 10-year experience.
    Maric LS, Knezovic I, Papic N, Mise B, Roglic S, Markovinovic L, Tesovic G.
    Rheumatol Int; 2015 Jun 04; 35(6):1053-8. PubMed ID: 25429794
    [Abstract] [Full Text] [Related]

  • 33. Analysis of Age, Sex, Lack of Response to Intravenous Immunoglobulin, and Development of Coronary Artery Abnormalities in Children With Kawasaki Disease in Japan.
    Takekoshi N, Kitano N, Takeuchi T, Suenaga T, Kakimoto N, Suzuki T, Kada TT, Shibuta S, Tachibana S, Murayama Y, Yamaga H, Suzuki H.
    JAMA Netw Open; 2022 Jun 01; 5(6):e2216642. PubMed ID: 35696166
    [Abstract] [Full Text] [Related]

  • 34. The prevention of coronary artery aneurysm in Kawasaki disease: a meta-analysis on the efficacy of aspirin and immunoglobulin treatment.
    Durongpisitkul K, Gururaj VJ, Park JM, Martin CF.
    Pediatrics; 1995 Dec 01; 96(6):1057-61. PubMed ID: 7491221
    [Abstract] [Full Text] [Related]

  • 35. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H, He Y, Rong X, Ren Y, Pan L, Chu M, Wu R, Shi H.
    Postgrad Med; 2018 May 01; 130(4):442-447. PubMed ID: 29745742
    [Abstract] [Full Text] [Related]

  • 36. Treatment Intensification in Patients With Kawasaki Disease and Coronary Aneurysm at Diagnosis.
    Dionne A, Burns JC, Dahdah N, Tremoulet AH, Gauvreau K, de Ferranti SD, Baker AL, Son MB, Gould P, Fournier A, Newburger JW, Friedman KG.
    Pediatrics; 2019 Jun 01; 143(6):. PubMed ID: 31048414
    [Abstract] [Full Text] [Related]

  • 37. Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
    Miyata K, Kaneko T, Morikawa Y, Sakakibara H, Matsushima T, Misawa M, Takahashi T, Nakazawa M, Tamame T, Tsuchihashi T, Yamashita Y, Obonai T, Chiga M, Hori N, Komiyama O, Yamagishi H, Miura M, Post RAISE group.
    Lancet Child Adolesc Health; 2018 Dec 01; 2(12):855-862. PubMed ID: 30337183
    [Abstract] [Full Text] [Related]

  • 38. Treatment and Coronary Artery Aneurysm Formation in Kawasaki Disease: A Per-Day Risk Analysis.
    van Stijn D, Korbee JM, Netea SA, de Winter VC, Zwinderman KAH, Kuipers IM, Kuijpers TW.
    J Pediatr; 2022 Apr 01; 243():167-172.e1. PubMed ID: 34968497
    [Abstract] [Full Text] [Related]

  • 39. Duration of high-dose aspirin therapy does not affect long-term coronary artery outcomes in Kawasaki disease.
    Migally K, Braunlin EA, Zhang L, Binstadt BA.
    Pediatr Res; 2018 Jun 01; 83(6):1136-1145. PubMed ID: 29554081
    [Abstract] [Full Text] [Related]

  • 40. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P, Hong-Hgam C, Khositseth A, Wanitkun S.
    J Med Assoc Thai; 2002 Nov 01; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.